The estimated Net Worth of Morton Goldberg is at least $221 millier dollars as of 12 November 2019. Morton Goldberg owns over 2,001 units of AB Active ETFs Inc stock worth over $72,518 and over the last 10 years he sold EYEG stock worth over $96,331. In addition, he makes $52,204 as Independent Director at AB Active ETFs Inc.
Sign up
Morton Goldberg EYEG stock SEC Form 4 insiders trading
Morton has made over 6 trades of the AB Active ETFs Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 1,961 units of EYEG stock worth $13,590 on 6 December 2019.
The largest trade he's ever made was exercising 33,775 units of AB Active ETFs Inc stock on 3 June 2016 worth over $21,954. On average, Morton trades about 3,691 units every 75 days since 2015. As of 12 November 2019 he still owns at least 1,961 units of AB Active ETFs Inc stock.
You can see the complete history of Morton Goldberg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Morton Goldberg biography
Dr. Morton F. Goldberg M.D. serves as Independent Director of the Company. He has served as a director since October 2008. Since 2003 he has served as the Joseph E. Green Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, to which position he was appointed to in 2003. From 1989 to 2003 he served as the Director and William Holland Wilmer Professor of Ophthalmology at the Wilmer Eye Institute. Prior to this, he was a Professor and Chairman of the Department of Ophthalmology at the University of Illinois College of medicine in Chicago for nearly 20 years. Dr. Goldberg trained at Johns Hopkins as a resident and chief resident, and holds a joint appointment at the Johns Hopkins Applied Physics Laboratory. He is also a past President of the Association for Research in Vision and Ophthalmology, the Macula Society, and the Association of University Professors of Ophthalmology. Dr. Goldberg received his undergraduate degree with honors from Harvard College and his MD with honors from Harvard Medical School.
What is the salary of Morton Goldberg?
As the Independent Director of AB Active ETFs Inc, the total compensation of Morton Goldberg at AB Active ETFs Inc is $52,204. There are 7 executives at AB Active ETFs Inc getting paid more, with Stephen From having the highest compensation of $601,340.
How old is Morton Goldberg?
Morton Goldberg is 82, he's been the Independent Director of AB Active ETFs Inc since 2008. There are no older and 9 younger executives at AB Active ETFs Inc.
What's Morton Goldberg's mailing address?
Morton's mailing address filed with the SEC is C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM, MA, 02452.
Insiders trading at AB Active ETFs Inc
Over the last 10 years, insiders at AB Active ETFs Inc have traded over $15,523,641 worth of AB Active ETFs Inc stock and bought 17,254,349 units worth $18,625,708 . The most active insiders traders include Capital, Llc Armistice Capi..., Peter Greenleaf et (Innoven Partenaires S.A.) .... On average, AB Active ETFs Inc executives and independent directors trade stock every 60 days with the average trade being worth of $19,985,138. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 30 July 2021, trading 260,963 units of EYEG stock currently worth $647,188.
What does AB Active ETFs Inc's logo look like?
Complete history of Morton Goldberg stock trades at AB Active ETFs Inc
AB Active ETFs Inc executives and stock owners
AB Active ETFs Inc executives and other stock owners filed with the SEC include:
-
Stephen From,
President, Chief Executive Officer, Director -
Michael Manzo,
Vice President - Engineering -
Sarah Romano,
Chief Financial Officer -
Paul Chaney,
Independent Chairman of the Board -
Praveen Tyle,
Independent Director -
Thomas Hancock,
Independent Director -
Bernard Malfroy-Camine,
Independent Director -
Morton Goldberg,
Independent Director -
Keith Maher,
Director -
Steven Boyd,
Director -
Brenda Mann,
VP of Research & Development -
Michael Garanzini,
Chief Commercial Officer -
Peter Greenleaf,
Director -
Barbara Wirostko,
Chief Medical Officer -
(Innoven Partenaires S.A.) ...,
10% owner -
Private Equity Natixis,
10% owner -
Thomas Balland,
Director -
Ventech B Fcpr,
10% owner -
Capital Ii Ventech,
10% owner -
Mounia Chaoui,
Director -
Ryan Randall Brenneman,
Chief Financial Officer -
Franz Obermayr,
Acting CEO -
Kenneth L Gayron,
Director -
Aron Shapiro,
Director -
Brian M. Strem,
President and CEO